Weight-Loss Drugs During Early Pregnancy: Study of 7.5 Lakh Pregnancies Reveals Surprising Findings
Taking popular weight-loss drugs during early pregnancy may not carry the same risks for every woman. A large new study suggests that the increased risk of premature birth associated with these medications was observed mainly among women using them to treat diabetes, rather than those taking them for weight management.
Published in the journal Human Reproduction Open, the study was conducted by researchers at Copenhagen University Hospital Hvidovre in Denmark.
Researchers analysed nationwide health records covering 756,636 pregnancies among 480,231 women between October 2009 and December 2023. The study examined accidental exposure to GLP-1 receptor agonists during the eight weeks before or after the beginning of the last menstrual period. Of the pregnancies analysed, 529 involved prescription records indicating possible exposure to these medications.
The findings revealed that women prescribed GLP-1 medications for diabetes had a higher likelihood of premature delivery compared with women without exposure.
Importantly, the adjusted odds of preterm birth were 84% higher among women prescribed semaglutide for diabetes and 70% higher among those prescribed liraglutide.
However, researchers found no statistically significant increase in premature birth risk among women taking these medications for weight management.
The analysis also examined pre-eclampsia, gestational diabetes, stillbirth, placental complications and babies born unusually large for their gestational age.
Most initially observed associations with pregnancy complications were no longer statistically significant after accounting for other health factors.
Researchers suggested that pre-existing diabetes, rather than the medications themselves, may help explain the increased risk of premature birth.
However, the observational study could not establish cause and effect, and prescription records could not confirm actual medication use.
The findings do not establish that GLP-1 medications are safe during pregnancy.
Researchers emphasised that existing recommendations to discontinue these medications before planned conception remain important, while further studies are needed to guide counselling after accidental exposure.
REFERENCE: Kathrine Vauvert R Hviid, Karina Banasik, Laust Hvas Mortensen, Sten Madsbad, Katrine Strandberg-Larsen, Nina Rica Wium Geiker, David Westergaard, Henriette Svarre Nielsen. Periconceptional GLP-1 receptor agonist exposure and obstetric outcomes: a Danish nationwide cohort study. Human Reproduction Open, 2026; 2026 (2) DOI: 10.1093/hropen/hoag015
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.